Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,454.40
(
0.41%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
99.05
(
0.28%
)
Bitcoin
70,870.76
(
-0.61%
)
News Focus
News Focus

Replies to post #202517 on Biotech Values

Replies to #202517 on Biotech Values
icon url

DewDiligence

07/11/16 12:19 PM

#202518 RE: Bickema #202517

EGRX—Next cycle FDA approval for Kangio in this context means that I expect EGRX will resubmit the 505b2 NDA (without new clinical trials) and will get FDA approval based on the review of the resubmitted NDA.